5-FU + Folinic Acid + Irinotecan + Cetuximab + Avelumab
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Treatment Related Cancer
Conditions
Treatment Related Cancer
Trial Timeline
Sep 27, 2019 → Oct 18, 2023
NCT ID
NCT05217069About 5-FU + Folinic Acid + Irinotecan + Cetuximab + Avelumab
5-FU + Folinic Acid + Irinotecan + Cetuximab + Avelumab is a phase 2 stage product being developed by Merck for Treatment Related Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT05217069. Target conditions include Treatment Related Cancer.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05217069 | Phase 2 | Completed |
Competing Products
20 competing products in Treatment Related Cancer